Neuberger Berman Group
ATRA icon

Neuberger Berman Group’s Atara Biotherapeutics ATRA Stock Holding History

Neuberger Berman Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-479
Closed -$8.31K – 1902
2024
Q1 		$8.31K Buy
479
+34
+8% +$604 ﹤0.01% 1823
2023
Q4 		$5.71K Buy
+445
New +$10.4K ﹤0.01% 1857
2019
Q4 		– Sell
-39,117
Closed -$13.8M – 1532
2019
Q3 		$13.8M Sell
39,117
-15,524
-28% -$5.79M 0.02% 660
2019
Q2 		$27.5M Buy
54,641
+2,375
+5% +$1.68M 0.03% 525
2019
Q1 		$51.9M Buy
52,266
+668
+1% +$621K 0.06% 388
2018
Q4 		$44.8M Buy
51,598
+2,856
+6% +$2.65M 0.06% 382
2018
Q3 		$50.4M Buy
48,742
+2,994
+7% +$2.93M 0.06% 407
2018
Q2 		$42M Buy
45,748
+1,969
+4% +$2.12M 0.05% 455
2018
Q1 		$42.7M Buy
43,779
+3,291
+8% +$3M 0.05% 444
2017
Q4 		$18.3M Sell
40,488
-4,114
-9% -$1.52M 0.02% 647
2017
Q3 		$18.5M Buy
44,602
+5,883
+15% +$2.22M 0.02% 632
2017
Q2 		$13.6M Buy
38,719
+5,258
+16% +$2.03M 0.02% 692
2017
Q1 		$17.2M Buy
33,461
+3,455
+12% +$1.43M 0.02% 634
2016
Q4 		$10.7M Buy
30,006
+2,457
+9% +$1.04M 0.01% 735
2016
Q3 		$14.7M Buy
27,549
+2,384
+9% +$1.29M 0.02% 674
2016
Q2 		$14.2M Buy
25,165
+3,870
+18% +$1.86M 0.02% 675
2016
Q1 		$10.1M Buy
21,295
+1,538
+8% +$692K 0.01% 747
2015
Q4 		$13M Buy
19,757
+810
+4% +$613K 0.02% 710
2015
Q3 		$14.9M Buy
18,947
+1,106
+6% +$1.35M 0.02% 704
2015
Q2 		$23.5M Sell
17,841
-30
-0.2% -$34.4K 0.03% 645
2015
Q1 		$18.6M Buy
17,871
+16,220
+982% +$10.7M 0.02% 716
2014
Q4 		$1.1M Buy
+1,651
New +$1.01M ﹤0.01% 1205

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Neuberger Berman Group's ATRA Position: Q2 2024 in Review

Neuberger Berman Group sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 479 shares — an estimated $8.31K sold.

Neuberger Berman Group first reported a position in ATRA in Q4 2014 and held it in 22 quarters. The position peaked at $51.9M in Q1 2019. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Neuberger Berman Group reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 479 Atara Biotherapeutics shares in Q2 2024, an estimated $8.31K.
  • Neuberger Berman Group first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 22 quarters.
  • Neuberger Berman Group's Atara Biotherapeutics position peaked at $51.9M in Q1 2019.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Neuberger Berman Group's 13F filing for Q2 2024, filed 13 Aug 2024.